<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758078</url>
  </required_header>
  <id_info>
    <org_study_id>09102020</org_study_id>
    <nct_id>NCT04758078</nct_id>
  </id_info>
  <brief_title>Inhaled Budesonide in Transient Tachypnea of the Newborn</brief_title>
  <official_title>Inhaled Budesonide in Transient Tachypnea of the Newborn: A Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makassed General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makassed General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from&#xD;
      delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late&#xD;
      preterm and full-term infants to neonatal intensive care units. Infant born by C-section and&#xD;
      those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma,&#xD;
      diabetes, or analgesia) are more prone to develop TTN. Conventional treatment involves&#xD;
      appropriate oxygen administration and continuous positive airway pressure in some cases.&#xD;
      Hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce&#xD;
      complications.&#xD;
&#xD;
      Objectives: This study aims to determine the effectiveness of inhaled budesonide in the&#xD;
      treatment of this disorder through determining whether it reduces the duration of oxygen&#xD;
      therapy and respiratory symptoms and shortens hospital stay in term infants with transient&#xD;
      tachypnea of the newborn&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of respiratory distress</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Transient tachypnea of the newborn clinical score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of time to spontaneous breathing</measure>
    <time_frame>with 48 hours</time_frame>
    <description>Time to spontaneous unsupported breathing of room air (in hours)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Respiratory Distress</condition>
  <arm_group>
    <arm_group_label>Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive nebulized 0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inhaled corticosteroids</intervention_name>
    <description>Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours</description>
    <arm_group_label>Corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nebulized 0.9% saline will be given four times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Late preterm and term infants (post-menstrual age â‰¥ 34 weeks) delivered by Cesarean&#xD;
             section or vaginal delivery&#xD;
&#xD;
          -  Diagnosis of transient tachypnea of the newborn&#xD;
&#xD;
          -  The need for Continuous positive airway pressure (CPAP) &gt;6 hours to obtain the oxygen&#xD;
             saturation &gt;92%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meconium aspiration syndrome;&#xD;
&#xD;
          -  Respiratory distress syndrome&#xD;
&#xD;
          -  Congenital heart Disease&#xD;
&#xD;
          -  Non respiratory disorders causing tachypnea (polycythemia or hypoglycemia) resolving&#xD;
             with treatment of the disorder&#xD;
&#xD;
          -  Pneumonia by chest x-ray&#xD;
&#xD;
          -  Suspected sepsis/bacteremia&#xD;
&#xD;
          -  Prenatal steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sirin Mneimneh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makassed General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sirin Mneimneh, MD</last_name>
    <phone>+9611636000</phone>
    <phone_ext>6317</phone_ext>
    <email>sirin.mneimneh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makassed General Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>+961</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirin Mneimneh, MD</last_name>
      <phone>+9611636000</phone>
      <phone_ext>6317</phone_ext>
      <email>sirin.mneimneh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makassed General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Sirin Mneimneh</investigator_full_name>
    <investigator_title>Pediatrician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachypnea</mesh_term>
    <mesh_term>Transient Tachypnea of the Newborn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

